Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2025-02-28 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the approval of a clinical trial for a new drug by the National Medical Products Administration. It details the drug's classification, intended use, research background, and potential impact on the company. The document is short (1352 characters) and serves as a regulatory announcement about a clinical trial approval, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed governance information. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about drug trial approval and company disclosure obligations.
2025-02-28 Chinese
昆药集团2025年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the 2025 second extraordinary shareholders meeting of Kunming Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results on a specific proposal, and legal compliance statements. There is no financial data or report content, only the official voting results and meeting procedural information. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2025-02-13 Chinese
北京德恒（昆明）律师事务所关于昆药集团股份有限公司2025年第二次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the convening, attendance, and voting procedures of KunYao Group Co., Ltd.'s 2025 second extraordinary general meeting of shareholders. It details the legality and validity of the meeting and the resolutions passed. The document does not contain financial statements or results but focuses on the legal aspects of the shareholders' meeting and voting results. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and confirms the legality of the meeting and resolutions.
2025-02-13 Chinese
昆药集团关于2024年年度业绩快报的公告
Earnings Release Classification · 95% confidence The document is titled as an announcement regarding the 2024 annual performance preliminary report of Kunming Pharmaceutical Group Co., Ltd. It contains unaudited preliminary consolidated financial data for the year 2024, including revenue, profit, net profit attributable to shareholders, and other financial metrics. The document explicitly states that the data is preliminary and unaudited, and the final audited data will be disclosed in the company's 2024 annual report. The document is relatively short (2336 characters) and serves as a performance update or earnings preview rather than a full annual report. It does not contain the full audited financial statements or comprehensive analysis typical of a 10-K or full Annual Report. Therefore, this document fits best as an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only.
2025-02-10 Chinese
昆药集团关于股东大会开设网络投票提示服务的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the provision of a network voting reminder service for an upcoming extraordinary shareholders' meeting scheduled for February 13, 2025. It references a prior notice about the meeting (announcement 2025-008) and explains the voting methods and reminder services to assist shareholders. The document does not contain financial data, management discussion, or detailed meeting materials but is an informational notice about the voting process for a shareholders' meeting. It is not a report, transcript, or financial statement. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about shareholder meeting logistics and voting facilitation.
2025-02-07 Chinese
昆药集团2025年第二次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the 2025 second extraordinary shareholders' meeting of KPC Pharmaceuticals, Inc. It contains detailed agenda, voting procedures, and a specific proposal regarding increasing the company's idle funds for investment and financial management. The content is focused on the meeting organization, shareholder voting, and proposal explanation rather than financial statements or earnings data. There is no indication of it being an annual or interim report, earnings release, or audit report. It is clearly a set of materials prepared for a shareholders' meeting, which fits the definition of AGM Information (AGM-R). The document length is about 5109 characters, which is consistent with a meeting material document rather than a brief announcement or a full report. Therefore, the classification is AGM Information (AGM-R) with high confidence.
2025-02-06 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.